Flossbach Von Storch SE purchased a new stake in CME Group Inc. (NASDAQ:CME - Free Report) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 1,155 shares of the financial services provider's stock, valued at approximately $306,000.
A number of other large investors have also recently bought and sold shares of CME. Wayfinding Financial LLC bought a new stake in CME Group in the first quarter valued at $25,000. New Age Alpha Advisors LLC grew its holdings in shares of CME Group by 50.0% during the fourth quarter. New Age Alpha Advisors LLC now owns 129 shares of the financial services provider's stock worth $30,000 after purchasing an additional 43 shares during the last quarter. Golden State Wealth Management LLC grew its holdings in shares of CME Group by 612.5% during the first quarter. Golden State Wealth Management LLC now owns 114 shares of the financial services provider's stock worth $30,000 after purchasing an additional 98 shares during the last quarter. Alpine Bank Wealth Management bought a new stake in shares of CME Group during the first quarter worth $32,000. Finally, Knuff & Co LLC bought a new stake in shares of CME Group during the fourth quarter worth $33,000. 87.75% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Several equities analysts have recently issued reports on CME shares. Erste Group Bank lowered CME Group from a "strong-buy" rating to a "hold" rating in a research note on Saturday, May 24th. Royal Bank Of Canada reiterated a "sector perform" rating and set a $269.00 price objective on shares of CME Group in a report on Thursday, April 3rd. Barclays raised their price objective on CME Group from $279.00 to $283.00 and gave the company an "equal weight" rating in a research report on Wednesday, April 23rd. Keefe, Bruyette & Woods boosted their price target on CME Group from $265.00 to $273.00 and gave the company a "market perform" rating in a research note on Thursday, April 24th. Finally, Oppenheimer boosted their price target on CME Group from $282.00 to $300.00 and gave the company an "outperform" rating in a research note on Wednesday, June 4th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and an average target price of $259.87.
View Our Latest Research Report on CME Group
Insider Activity at CME Group
In other news, Director William R. Shepard bought 256 shares of the firm's stock in a transaction on Wednesday, June 25th. The stock was acquired at an average cost of $270.53 per share, with a total value of $69,255.68. Following the completion of the transaction, the director directly owned 258,196 shares of the company's stock, valued at $69,849,763.88. This represents a 0.10% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel Jonathan L. Marcus sold 390 shares of the firm's stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $277.50, for a total value of $108,225.00. Following the completion of the sale, the general counsel directly owned 6,708 shares of the company's stock, valued at $1,861,470. This represents a 5.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 13,400 shares of company stock worth $3,680,610 over the last quarter. 0.30% of the stock is owned by company insiders.
CME Group Price Performance
CME stock traded up $0.01 during midday trading on Wednesday, reaching $275.64. 2,841,477 shares of the stock were exchanged, compared to its average volume of 2,196,408. The stock has a market capitalization of $99.33 billion, a PE ratio of 27.73, a P/E/G ratio of 3.83 and a beta of 0.44. CME Group Inc. has a 52 week low of $193.17 and a 52 week high of $290.79. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.02 and a quick ratio of 1.02. The company has a fifty day moving average price of $276.76 and a 200 day moving average price of $258.61.
CME Group (NASDAQ:CME - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The financial services provider reported $2.80 earnings per share for the quarter, topping analysts' consensus estimates of $2.61 by $0.19. The business had revenue of $1.64 billion for the quarter, compared to analyst estimates of $1.56 billion. CME Group had a return on equity of 14.03% and a net margin of 57.71%. CME Group's quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.50 EPS. As a group, analysts expect that CME Group Inc. will post 10.49 EPS for the current fiscal year.
CME Group Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Wednesday, June 25th. Shareholders of record on Monday, June 9th were given a $1.25 dividend. The ex-dividend date of this dividend was Monday, June 9th. This represents a $5.00 dividend on an annualized basis and a dividend yield of 1.81%. CME Group's dividend payout ratio (DPR) is presently 50.30%.
About CME Group
(
Free Report)
CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.
Featured Articles

Before you consider CME Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CME Group wasn't on the list.
While CME Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.